2-hydroxy-4-(trifluoromethoxy)benzoic acid | 851341-52-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-hydroxy-4-(trifluoromethoxy)benzoic acid
• 英文别名: 2-Hydroxy-4-trifluoromethoxy-benzoic acid
• CAS: 851341-52-1
• 化学式: C₈H₅F₃O₄
• 分子量: 222.121
• InChiKey: SJLOQRYZOOOBKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-hydroxy-4-(trifluoromethoxy)benzoic acid 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成 ethyl [2-(2-chloro-ethoxy)-4-trifluoromethoxy]benzoate
  参考文献：
  名称：

  Structure–Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).

  摘要：

  The (S)-2-nitro-6-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine named PA-824 (1) has demonstrated antitubercular activity in vitro and in animal models and is currently in clinical trials. We synthesized derivatives at three positions of the 4-(trifluoromethoxy)benzylamino tail, and these were tested for whole-cell activity against both replicating and nonreplicating Mycobacterium tuberculosis (Mtb). In addition, we determined their kinetic parameters as substrates of the deazaflavin-dependent nitroreductase (Ddn) from Mtb that reductively activates these pro-drugs. These studies yielded multiple compounds with 40 nM aerobic whole cell activity and 1.6 mu M anaerobic whole cell activity: 10-fold improvements over both characteristics from the parent molecule. Some of these compounds exhibited enhanced solubility with acceptable stability to microsomal and in vivo metabolism. Analysis of the conformational preferences of these analogues using quantum chemistry suggests a preference for a pseudoequatorial orientation of the linker and lipophilic tail.

  DOI：

  10.1021/jm1010644
• 作为产物：
  描述：

  1-(甲氧基甲氧基)-3-(三氟甲氧基)苯 在 盐酸 、 四丁基氟化铵 、 仲丁基锂 作用下， 以 四氢呋喃 、 乙醚 、 环己烷 、 水 为溶剂， 反应 8.0h， 生成 2-hydroxy-4-(trifluoromethoxy)benzoic acid
  参考文献：
  名称：

  含卤素酚的位点选择性官能化：面向多样性的有机金属合成中的一项练习

  摘要：

  面向多样性的有机合成的有机金属方法经受了进一步的测试，这次是在苯酚系列中进行的。选择的模型化合物是2,3,6-三氟苯酚，（三氟甲氧基）苯酚的三个异构体和氯苯酚的三个异构体。任选地选择性金属化和保护基团控制的金属化的组合能够在每种情况下选择性生成几种异构中间体，并随后将其转化为官能化衍生物，特别是羟基苯甲酸。

  DOI：

  10.1016/j.tet.2004.10.103

文献信息

• [EN] AMIDE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS D'AMIDE COMME BLOQUEURS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2013161308A1

  公开（公告）日：2013-10-31

  The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及酰胺衍生物，具有对电压门控钠通道（如TTX-S通道）的阻塞活性，可用于治疗或预防涉及电压门控钠通道的疾病和疾病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗涉及电压门控钠通道的疾病中使用这些化合物和组合物。
• N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS FOR THEIR THERAPEUTIC USE
  申请人：KEIL Stefanie

  公开号：US20090054494A1

  公开（公告）日：2009-02-26

  The present invention comprises N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their physiologically acceptable salts and functional derivatives that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, And the isomers thereof wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及N-[1,3,4]-噻二唑-2-基苯磺酰胺、其生理上可接受的盐和功能衍生物，它们表现出过氧化物酶体增殖物激活受体(PPAR) PPARδ和PPARγ激动剂活性。发明中的化合物的结构由下式I定义，以及其异构体，其中各种取代基在此定义，包括其生理上可接受的盐。还公开了制备这些化合物的方法。这些化合物适用于治疗涉及脂肪酸代谢和葡萄糖利用障碍、涉及胰岛素抵抗的疾病，以及中枢和周围神经系统的脱髓鞘和其他神经退行性疾病的治疗。
• BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE
  申请人：SCHOENAFINGER Karl

  公开号：US20100022603A1

  公开（公告）日：2010-01-28

  The present invention comprises bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, their functional derivatives thereof as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the preparation of compounds are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及双环芳基磺酸[1,3,4]-噻二唑-2-基酰胺及其功能衍生物，以及其生理上可接受的盐和药物组合物，具有过氧化物酶体增殖激活受体（PPAR）PPARδ和PPARγ激动剂活性。本发明化合物的结构由以下式I定义，其中各种取代基在此定义，包括其生理上可接受的盐。本发明还公开了制备该化合物的方法。该化合物适用于治疗与脂肪酸代谢和葡萄糖利用障碍有关的疾病，涉及胰岛素抵抗以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE THERAPEUTIC USE THEREOF
  申请人：SCHOENAFINGER Karl

  公开号：US20080280959A1

  公开（公告）日：2008-11-13

  The present invention comprises cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, their functional derivatives as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below, wherein the various R1-R9 substituents are defined herein. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明包括环状N-[1,3,4]-噻二唑-2-基苯磺酰胺，它们的功能衍生物以及其生理上可接受的盐和药物组成物，具有过氧化物酶体增殖物激活受体（PPAR）PPARδ和PPARγ激动剂活性。该发明化合物的结构由下式I定义，其中各种R1-R9取代基在此定义。本发明还揭示了化合物的制备过程。该化合物适用于治疗与脂肪酸代谢和葡萄糖利用障碍有关的疾病，涉及胰岛素抵抗以及中枢和周围神经系统的脱髓鞘和其他神经退行性疾病。
• AMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：RaQualia Pharma Inc.

  公开号：US20150105393A1

  公开（公告）日：2015-04-16

  The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及酰胺衍生物，其具有对电压门控钠通道（如TTX-S通道）的阻滞活性，并且在治疗或预防涉及电压门控钠通道的疾病和疾病时非常有用。 本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及电压门控钠通道的这些疾病中使用这些化合物和组合物的用途。